WESTLAKE VILLAGE, Calif.—Patrick Burnett, Senior Vice President and Chief Medical (TASE:PMCN) Officer of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), recently sold shares of the company's stock. According to a filing with the Securities and Exchange Commission, Burnett sold 15,441 shares on November 4, 2024, at an average price of $8.6842 per share, totaling approximately $134,092.
The transaction was conducted under the company's mandatory sell-to-cover requirements to meet tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). Following the sale, Burnett retains ownership of 179,418 shares in the company.
Arcutis Biotherapeutics, headquartered in Westlake Village, California, focuses on developing innovative therapies for dermatological conditions.
In other recent news, Arcutis Biotherapeutics has achieved significant milestones. The company's Q2 2024 earnings revealed a 43% increase in net product revenues, reaching $30.9 million, largely driven by prescription growth for dermatology products, ZORYVE cream and foam. Health Canada has approved ZORYVE foam 0.3% for seborrheic dermatitis treatment, marking the first new topical treatment mechanism for the condition in Canada in over 20 years.
Analyst firms Mizuho (NYSE:MFG) Securities, TD (TSX:TD) Cowen, and Jefferies have maintained a positive outlook on Arcutis. Jefferies has initiated a Buy rating, citing the company's potential for growth, while Mizuho Securities reiterated an Outperform rating, expecting a strong Q3 2024 performance.
The U.S. Food and Drug Administration has accepted a Supplemental New Drug Application for ZORYVE foam for scalp and body psoriasis, with an action date set for May 2025. Additionally, results from two Phase 3 studies evaluating the efficacy and safety of ZORYVE cream for mild to moderate atopic dermatitis have been published. These are among the recent developments for Arcutis Biotherapeutics.
InvestingPro Insights
While Patrick Burnett's recent stock sale was part of a routine tax-related transaction, it's worth examining Arcutis Biotherapeutics' financial position to gain a broader perspective on the company's performance.
According to InvestingPro data, Arcutis has shown impressive revenue growth, with a staggering 1032.9% increase in the last twelve months as of Q2 2024. This substantial growth aligns with an InvestingPro Tip indicating that analysts anticipate sales growth in the current year, suggesting a positive trajectory for the company's top line.
Another notable metric is Arcutis' gross profit margin, which stands at an impressive 92.32% for the same period. This aligns with another InvestingPro Tip highlighting the company's "impressive gross profit margins," indicating efficient cost management in its core operations.
However, investors should note that despite strong revenue growth and high margins, Arcutis is not yet profitable. The company reported an operating loss of $179.77 million in the last twelve months, with a negative operating income margin of 136.13%. This reflects the InvestingPro Tip that the company is "quickly burning through cash," which is not uncommon for biopharmaceutical companies in the development stage.
For those interested in a more comprehensive analysis, InvestingPro offers additional tips and insights. In fact, there are 10 more InvestingPro Tips available for Arcutis Biotherapeutics, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.